Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 9/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.50 |
| ▸ | TSPO | P30536 | 2/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864512 | 0.93 | TSPO (0.52) | PLA2G2AMTNR1AMTNR1BTSPOHCRTR1 | |
| SCHEMBL5508890 | 0.89 | PLA2G2A (0.55) | PLA2G2AMTNR1AMTNR1BTSPOHCRTR1 | |
| SCHEMBL17286656 | 0.85 | PLA2G2A (0.40) | PLA2G2AMTNR1AMTNR1BHCRTR1HCRTR2 | |
| SCHEMBL6690535 | 0.85 | TSPO (0.57) | PLA2G2AMTNR1AMTNR1BTSPOHCRTR1 | |
| SCHEMBL14598609 | 0.82 | PLA2G2A (0.47) | PLA2G2AMTNR1AMTNR1BTSPOHCRTR1 | |
| SCHEMBL14598616 | 0.81 | PLA2G2A (0.47) | PLA2G2AMTNR1AMTNR1BTSPOHCRTR1 | |
| SCHEMBL14598610 | 0.81 | PLA2G2A (0.47) | PLA2G2AMTNR1AMTNR1BTSPOHCRTR1 | |
| SCHEMBL5864649 | 0.81 | PLA2G2A (0.43) | PLA2G2ATSPO | |
| SCHEMBL14598615 | 0.81 | PLA2G2A (0.46) | PLA2G2AMTNR1AMTNR1BTSPOHCRTR1 | |
| SCHEMBL5507320 | 0.80 | PLA2G2A (0.59) | PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160909-B2 | Cyclopenta[b]indole derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160909-B2 | Cyclopenta[b]indole derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050026988-A1 | Cyclopenta'b! indole derivatives as spla inhibitors | KINNICK MICHAEL DEAN (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026988-A1 | Cyclopenta'b! indole derivatives as spla inhibitors | PTGIS, PLA2G4A, PLA2G4B | PLA2G2A 28/4885MTNR1A 788/4885MTNR1B 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.